CSL (ASX:CSL) share price falls amid ongoing AstraZeneca uncertainty

The CSL (ASX:CSL) share price is slumping today as ongoing uncertainty over the side effects of the AstraZeneca vaccine continue.

| More on:
falling healthcare asx share price Mesoblast capital raising

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) shares are edging lower today as ongoing uncertainty over the side effects of the AstraZeneca COVID-19 vaccine continues. At the time of writing, the CSL share price is trading 0.11% lower at $265.22.

CSL is involved in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. The company advised late last month it is set to produce more than 1 million doses of the AstraZeneca vaccine per week. 

It was commissioned by the government to produce 50 million doses of the AstraZeneca vaccine, before the vaccine was found to create a one-in-200,000 chance of blood clots – termed thrombosis with thrombocytopenia – around the brain and abdomen.

This led to the government's health body ruling out use of the vaccine for anyone under 50-years-old, including frontline health workers, but that uncertainty has led to the widespread cancellation of vaccine appointments across the country.

One Australian patient suffered thrombosis and a low platelet count after being vaccinated on 22 March.

The government has ordered an additional 20 million doses of the Pfizer vaccine, bringing the total to 40 million, which are due to arrive late this year.

This is leading to concerns that many of the vaccine doses CSL is producing will go to waste. Furthermore, the government has now thrown out any timeframe around rolling out the vaccine.

CSL said in a statement on 8 April that it was still committed to producing the AstraZeneca vaccine.

 "[CSL is] committed to meeting its contracted arrangements with the Australian Government and AstraZeneca for locally produced AstraZeneca COVID-19 vaccines."

"We will continue our focused and important efforts to manufacture this vaccine which remains critical for the protection of our most vulnerable populations."

CSL share price snapshot

Despite initial dips in the CSL share price as vaccine targets were changed and AstraZeneca uncertainty pervaded news headlines, the company's shares have continued to rise over the past month.

At the time of writing, the CSL share price is up by 0.74% this week and 3.66% over the past month.

However, it's worth noting that the company's shares have been slipping since the outbreak of the COVID-19 pandemic. Over the past 12 months, the CSL share price has lost around 19% and it's down around 12% against the healthcare sector during that same period.

Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »